相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Editorial Material
Infectious Diseases
Eskild Petersen et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Multidisciplinary Sciences
Jessica A. Plante et al.
Summary: The D614G substitution in the SARS-CoV-2 spike protein enhances viral replication and infectivity in human lung epithelial cells, primary airway tissues, and hamsters. This variant may increase transmission in the upper respiratory tract and doesn't seem to significantly reduce vaccine efficacy. Further research on therapeutic antibodies targeting the circulating G614 virus is recommended.
Letter
Immunology
Prerna Arora et al.
CELLULAR & MOLECULAR IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Merryn Voysey et al.
Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.
Article
Medicine, General & Internal
D. M. Weinreich et al.
Summary: Recent data indicate that complications and death from Covid-19 may be related to high viral loads. In this trial involving nonhospitalized patients, a cocktail of two neutralizing monoclonal antibodies (REGN-COV2) reduced viral load, with a greater effect in patients with no immune response or high viral load at baseline. Safety outcomes were similar between REGN-COV2 dose groups and the placebo group.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
S. F. Lumley et al.
Summary: In a longitudinal study of seropositive and seronegative health care workers undergoing asymptomatic and symptomatic SARS-CoV-2 testing, the presence of anti-spike or anti-nucleocapsid IgG antibodies was associated with a substantially reduced risk of SARS-CoV-2 reinfection in the ensuing 6 months.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Nadine Krueger et al.
Summary: Domestic and predatory cats are highly susceptible to SARS-CoV-2 infection, with strong viral replication observed in nasal mucosa and trachea, primarily in epithelial cells. Lower efficiency of replication was found in lung tissue. High ACE2 levels in the nose and trachea suggest a correlation with susceptibility to SARS-CoV-2 in felines.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
News Item
Medicine, General & Internal
Jennifer Abbasi
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Multidisciplinary Sciences
Pei Li et al.
Summary: Bat coronavirus RaTG13 shares high genome similarity with SARS-CoV-2 and uses human ACE2 for entry. Various animal ACE2s, including Rhinolophus affinis bat ACE2, can act as entry receptors for SARS-CoV-2 and RaTG13. Mutagenesis analysis identified critical residues in spike proteins for recognition of host ACE2. These findings contribute to understanding coronavirus entry, host range, and virus-host coevolution.
Article
Biochemistry & Molecular Biology
Qianqian Li et al.
Summary: The 501Y.V2 variants of SARS-CoV-2 with multiple mutations are rapidly spreading from South Africa to other countries, showing reduced susceptibility to neutralizing antibodies and potential compromise of monoclonal antibodies and vaccines. Enhanced infectivity in murine ACE2-overexpressing cells suggests the possibility of transmission to mice.
Article
Microbiology
Zhuoming Liu et al.
Summary: The study found that antibodies targeting the SARS-CoV-2 spike protein have escape mutations, different monoclonal antibodies have unique resistance profiles, some mutants are resistant to multiple antibodies while some variants can escape neutralization by convalescent sera. Comparing antibody-mediated mutations with circulating SARS-CoV-2 sequences revealed substitutions that may weaken neutralizing immune responses in some individuals, warranting further investigation.
CELL HOST & MICROBE
(2021)
Article
Multidisciplinary Sciences
Flora Graham
Article
Biochemistry & Molecular Biology
Shuo Feng et al.
Summary: Defined levels of SARS-CoV-2-specific binding and neutralizing antibodies elicited by the COVID-19 vaccine were identified as correlates of protection against symptomatic infection. Higher levels of immune markers were correlated with a reduced risk of symptomatic infection. The data can be used to extrapolate efficacy estimates to new populations.
Article
Medicine, General & Internal
Anil Gupta et al.
Summary: In this study, among nonhospitalized patients with symptomatic Covid-19, sotrovimab treatment significantly reduced the risk of disease progression leading to hospitalization or death compared to placebo. Patients receiving sotrovimab also had a lower rate of serious adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Hiam Chemaitelly et al.
Summary: In a study conducted in Qatar involving over 900,000 participants, vaccine effectiveness peaked at 77.5% in the first month after the second dose. However, it declined afterwards to as low as 20% in months 5 through 7 after vaccination, while protection against severe Covid-19 remained above 90% for at least 6 months.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Virology
Yufei Zhang et al.
Summary: This study showed that aged BALB/c mice infected with SARS-CoV-2 exhibited rapid viral replication leading to pneumonia, while young mice quickly cleared the virus with no pathological changes in the lungs. Aged mice also had stronger cytokine responses, particularly interleukin 6 and interferon gamma, compared to young mice. The research further demonstrated the potential of using aged BALB/c mice as a model for understanding SARS-CoV-2 pathogenesis and testing vaccines and antiviral agents.
JOURNAL OF VIROLOGY
(2021)
Article
Multidisciplinary Sciences
Liping Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Multidisciplinary Sciences
Bin Zhou et al.
Summary: Research has shown that the D614G substitution in the spike protein of SARS-CoV-2 leads to increased binding and replication potential in humans, as well as significantly higher replication and transmissibility in different animal models, providing an explanation for the global prevalence of this variant in the COVID-19 pandemic.
Article
Multidisciplinary Sciences
Zijun Wang et al.
Summary: Volunteers who received the Moderna or Pfizer-BioNTech vaccine showed high levels of antibodies and memory B cell responses against SARS-CoV-2, with activity similar to individuals who had recovered from natural infection. However, their efficacy against specific SARS-CoV-2 variants was reduced, indicating a potential need for periodic updates to mRNA vaccines to maintain clinical efficacy.
Article
Multidisciplinary Sciences
Kai Kupferschmidt
Article
Medicine, General & Internal
Raymond A. Harvey et al.
Summary: Understanding the impact of serum antibodies to SARS-CoV-2 on infection susceptibility is crucial for identifying at-risk populations and vaccine deployment. Results of the study suggest that individuals with positive antibody test results initially had a higher likelihood of positive NAAT results, but this likelihood decreased significantly over time, indicating that seropositivity may be associated with protection from infection, though the duration of this protection remains uncertain and may decrease over time.
JAMA INTERNAL MEDICINE
(2021)
Article
Multidisciplinary Sciences
Shihui Sun et al.
Summary: The study presents a novel mouse-adapted SARS-CoV-2 strain, MASCp36, as a model for investigating the pathogenicity, evolution, and adaptation of the virus. Through deep sequencing and cryo-electron microscopy analysis, the molecular basis of structural changes and receptor binding mechanism at a biological level are revealed.
NATURE COMMUNICATIONS
(2021)
News Item
Medicine, General & Internal
Ingrid Torjesen
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Cell Biology
Prerna Arora et al.
Summary: The Delta variant, B.1.617.2, has spread to over 80 countries, showing evasion of antibodies, resistance to certain therapies, and enhanced transmissibility.
Article
Cell Biology
Adam K. Wheatley et al.
Summary: Potent neutralizing monoclonal antibodies are effective in treating COVID-19 by targeting specific sites on the viral spike protein. Research has identified antibodies that can improve SARS-CoV-2 infection and highlighted certain antibodies that remain effective against current VOCs. These findings suggest potential future therapeutics for combating SARS-CoV-2.
Article
Biochemistry & Molecular Biology
Matthew McCallum et al.
Summary: The study identifies 41 human monoclonal antibodies that recognize the N-terminal domain of the SARS-CoV-2 spike protein and exhibit strong neutralizing activity. These antibodies inhibit cell-to-cell fusion, activate effector functions, and protect animals from virus challenge, highlighting the importance of NTD-specific neutralizing antibodies for protective immunity and vaccine development. Several SARS-CoV-2 variants with mutations in the NTD supersite suggest ongoing selective pressure on the virus.
Article
Biochemistry & Molecular Biology
Markus Hoffmann et al.
Summary: The emerging SARS-CoV-2 variants may exhibit resistance to existing neutralizing antibodies and treatments, which could have significant implications for pandemic containment efforts.
Editorial Material
Medicine, General & Internal
Florian Krammer
Article
Medicine, General & Internal
Christian Holm Hansen et al.
Summary: The study investigated the protection against SARS-CoV-2 reinfection, with results showing an 80.5% protection rate for individuals previously infected. Even in the population aged 65 years and older, the protection rate against reinfection reached 47.1%, with no significant differences observed by gender or time since infection.
Article
Medicine, General & Internal
Victoria Jane Hall et al.
Summary: This study investigated whether antibodies against SARS-CoV-2 were associated with a decreased risk of symptomatic and asymptomatic reinfection. It found that individuals with a previous history of SARS-CoV-2 infection had an 84% lower risk of reinfection, with a median protective effect lasting for 7 months following primary infection.
Article
Cell Biology
Bryan E. Jones et al.
Summary: LY-CoV555 is a novel neutralizing antibody derived from a convalescent patient with COVID-19, showing high affinity binding, potent inhibition of ACE2 binding, and strong neutralizing activity. This antibody has entered clinical trials and is being evaluated for various COVID-19 prevention and treatment indications.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Article
Cell Biology
Markus Hoffmann et al.
Summary: Transmission of SARS-CoV-2 from humans to farmed mink and back raises concerns of genetic variants with potential increased threat to human health. Mutations in the spike protein of SARS-CoV-2 from mink allow efficient entry into human cells and inhibition by ACE2, while mutation Y453F reduces neutralization by certain antibodies authorized for COVID-19 therapy. Antibody responses induced by infection or specific treatments might not offer adequate protection against SARS-CoV-2 variants from mink.
Article
Multidisciplinary Sciences
Rachael A. Mansbach et al.
Summary: The emergence of the G-form variant of COVID-19 has led to a more infectious strain with increased viral loads, likely due to changes in protein energetics favoring infection-capable states and enhanced exposure of the receptor binding domain. These findings are crucial for vaccine design.
Article
Medicine, General & Internal
Kun Huang et al.
Summary: By passaging SARS-CoV-2 in BALB/c mice, researchers obtained a mouse-adapted virus strain with increased infectivity and severe interstitial pneumonia in mice; mutations Q493K and Q498H in the RBD of the virus enhanced its binding affinity to mouse ACE2; the study tentatively confirmed the antiviral activity of TLR7/8 agonist Resiquimod against SARS-CoV-2 in vitro and in vivo.
Letter
Medicine, General & Internal
Georg M. N. Behrens et al.
Article
Biochemistry & Molecular Biology
Joana Barros-Martins et al.
Summary: A study found that booster vaccination with BNT162b2 in healthcare professionals previously vaccinated with ChAdOx-1 nCoV-19 elicited more neutralizing antibodies and higher frequencies of virus-specific T cells. Additionally, BNT162b2 induced high titers of neutralizing antibodies against variants of concern, such as B.1.1.7, B.1.351, and P.1.
Review
Genetics & Heredity
Kaiming Tao et al.
Summary: The emergence of multiple SARS-CoV-2 variants has significant impacts on the epidemiological and clinical aspects of the COVID-19 pandemic, including increased virus transmission rates, heightened risk of reinfection, and reduced effectiveness of neutralizing antibodies and vaccines. These variants have introduced new challenges to COVID-19 research, necessitating additional avenues of laboratory, epidemiological, and clinical studies.
NATURE REVIEWS GENETICS
(2021)
Review
Microbiology
William T. Harvey et al.
Summary: The evolution of SARS-CoV-2 has been characterized by the emergence of mutations and variants that impact virus characteristics. Manufacturers are preparing for possible updates to vaccines in response to changes in the virus population, and it is crucial to monitor genetic and antigenic changes alongside experiments to understand the impacts of mutations.
NATURE REVIEWS MICROBIOLOGY
(2021)
Article
Medicine, General & Internal
M. Dougan et al.
Summary: In this phase 3 trial, the combination of bamlanivimab plus etesevimab was found to reduce the incidence of Covid-19-related hospitalization and death among high-risk ambulatory patients compared to placebo, and also accelerated the decline in SARS-CoV-2 viral load.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Kizzmekia S. Corbett et al.
Summary: In nonhuman primates (NHPs), vaccination with mRNA-1273 induces dose-dependent antibody responses, leading to a significant reduction in viral replication post SARS-CoV-2 challenge. Replication of the virus correlates strongly with antibody levels and neutralizing activity, with lower levels required in the lower airway than in the upper airway. Passive transfer of mRNA-1273-induced IgG is sufficient to provide protection, indicating that humoral immune responses induced by mRNA-1273 vaccine are effective against SARS-CoV-2 in NHPs.
Article
Cell Biology
Bo Meng et al.
Summary: The Delta H69N70 mutation in SARS-CoV-2 spike protein increases infectivity and partially rescues immune escape mutations that impair infectivity. Continued surveillance and research on deletions with functional effects are necessary.
Article
Multidisciplinary Sciences
Peng Zhou et al.
Article
Biochemistry & Molecular Biology
Vanessa Monteil et al.
Article
Biochemistry & Molecular Biology
Markus Hoffmann et al.
Article
Biochemistry & Molecular Biology
Markus Hoffmann et al.
Article
Multidisciplinary Sciences
Rui Shi et al.
Article
Multidisciplinary Sciences
Dora Pinto et al.
Article
Biochemistry & Molecular Biology
Bette Korber et al.
Article
Immunology
Fabian Schmidt et al.
JOURNAL OF EXPERIMENTAL MEDICINE
(2020)
Article
Multidisciplinary Sciences
Johanna Hansen et al.
Article
Multidisciplinary Sciences
Yongfei Cai et al.
Article
Microbiology
Amin Addetia et al.
JOURNAL OF CLINICAL MICROBIOLOGY
(2020)
Article
Multidisciplinary Sciences
Yixuan J. Hou et al.
Article
Virology
Hannah Kleine-Weber et al.
JOURNAL OF VIROLOGY
(2019)
Article
Multidisciplinary Sciences
Constantin Brinkmann et al.
Article
Multidisciplinary Sciences
Marianne Berger Rentsch et al.
